Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis

Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis

IntroductionHepatocellular carcinoma (HCC) is a high-grade malignant disease with unfavorable prognosis, and although surgical therapy is necessary, not all patients with HCC are suitable candidates for surgery. Downstaging as preoperative therapeutic strategy, which can convert unresectable HCC int...

Full description

Bibliographic Details
Main Authors:	Xinyu Chen, Lin Lai, Jiazhou Ye, Lequn Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-11-01
Series:	Frontiers in Oncology
Subjects:	hepatic resection (HR) downstaging hepatocellular carcinoma unresectable meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.740762/full

Similar Items

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
by: Hui-Chuan Sun, et al.
Published: (2021-11-01)

Rational design of NIR-II molecule-engineered nanoplatform for preoperative downstaging and imaging-guided surgery of orthotopic hepatic tumor
by: Qi Pan, et al.
Published: (2023-12-01)

Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
by: Yin Long, et al.
Published: (2023-12-01)

Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases
by: Lin Shang, et al.
Published: (2022-09-01)

Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features
by: Si-Yuan Wang, et al.
Published: (2023-09-01)

Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or “Wait and See” Strategy?
by: Alessandro Vitale, et al.
Published: (2021-05-01)

Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors
by: Qimeng Gao, et al.
Published: (2021-12-01)

Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis
by: Victor Lopez-Lopez, et al.
Published: (2023-04-01)

Bridging and downstaging with TACE in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant
by: Chao Yin, et al.
Published: (2023-03-01)

From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies
by: Chen Liang, et al.
Published: (2023-12-01)

Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes
by: Marcello Di Martino, et al.
Published: (2022-10-01)

Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: a retrospective controlled study
by: Song Chen, et al.
Published: (2023-11-01)

International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria
by: Helena Degroote, et al.
Published: (2021-10-01)

Hepatosellüler karsinomada bridging veya downstaging sonrası karaciğer transplantasyonu ile direkt transplantasyon stratejilerinin sağkalım üzerine etkilerinin karşılaştırılması
by: Tuğsan Ballı, et al.
Published: (2019-12-01)

Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis
by: Daopeng Yang, et al.
Published: (2020-11-01)

FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
by: Iason Psilopatis, et al.
Published: (2023-01-01)

Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study
by: Jian Huang, et al.
Published: (2023-07-01)

A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy
by: Baojiang Liu, et al.
Published: (2023-08-01)

Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis
by: Mrudula B. Glassberg, et al.
Published: (2019-06-01)

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
by: Xiao Y, et al.
Published: (2023-11-01)

Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy
by: Bahareh Farasati Far, et al.
Published: (2023-03-01)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
by: Yue Han, et al.
Published: (2021-10-01)

Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
by: Roberto Minici, et al.
Published: (2021-04-01)

Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!
by: Vijay Maruti Patil, et al.
Published: (2020-10-01)

Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Teng-Kai Yang, et al.
Published: (2022-10-01)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
by: Pei-Chang Lee, et al.
Published: (2020-01-01)

Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review
by: Marco Massani, et al.
Published: (2021-06-01)

Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
by: Ahmed Z, et al.
Published: (2023-10-01)

Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials
by: Han Dong, et al.
Published: (2023-06-01)

Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis
by: Qing Lei, et al.
Published: (2022-09-01)

Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
by: Masayuki Okuno, et al.
Published: (2023-08-01)

Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study
by: Alessandro Beleù, et al.
Published: (2019-02-01)

Downstaging and Conversation Strategy for Advanced Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus: TACE, 125I Seed Implantation, and RFA for Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus
by: Zhao XH, et al.
Published: (2023-02-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

The role of upfront primary tumor resection in asymptomatic patients with unresectable stage IV colorectal cancer: A systematic review and meta-analysis
by: Zongyu Liang, et al.
Published: (2023-01-01)

Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
by: Shouhao Zhou, et al.
Published: (2023-02-01)

The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine
by: Alina Wilkowska, et al.
Published: (2022-11-01)

The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?
by: Michelle Ju, et al.
Published: (2019-09-01)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
by: Qi Li, et al.
Published: (2022-02-01)

Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis
by: Kun Liu, et al.
Published: (2023-01-01)